[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urinary-tract-infection-bacterial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urinary-tract-infection-bacterial":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,86,116,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100651551","clinical-impact-of-a-machine-learning-decision-support-system-for-empirical-antibiotic-therapy-100651551",false,"NCT07762378","Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy","Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy: A Prospective Quasi-Experimental Study","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years)\n* Admitted to the Nephrology, Oncology or ICU wards\n* Diagnosis of sepsis, pneumonia and\u002For UTI\n* Empirical antibiotics prescribed\n\nExclusion Criteria:\n\n* informed consent obtained \\> 48 hours since the infection onset\n* beta-lactam allergy\n* infection syndrome other than sepsis, pneumonia or UTI\n* confirmed no-bacterial infection\n* death within the first 48 hours of inclusion or imminent risk of death at time of the inclusion\n* pregnancy and\u002For breastfeeding\n* inclusion in a clinical trial of antimicrobial treatment","ALL","18 Years",{"count":19,"type":20},486,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this quasi-experimental study is to analyze if a Machine Learning Clinical Decision Support System can improve the empirical antibiotic treatment in patients with pneumonia, urinary tract infection and \u002F or sepsis.\n\nThe main questions it aims to answer are:\n\n* Primary outcome: clinical success defined as clinical cure (resolution of all signs and symptoms related to infection); no complications until day 30 (recurrence, or development of adverse events- AEs-); no new acquisition of MDROs; and survival at day 30.\n* Secondary outcomes: a subgroup analysis of the primary outcome according to the department participants, infectious syndrome, severity of the infection assessed by the SOFA score, and in microbiological confirmed infections. In microbiological confirmed infections, desirability of Outcome Ranking (DOOR) for the Management of Antimicrobial Therapy (MAT) according to the beta-lactam classification\n\nResearchers will compare a pre-intervention group with a post-intervention to see if improve in the DOOR MAT score\n\nParticipants in the post-intervention group will:\n\n• Received empirical antibiotic therapy prescribed by their treating physicians according to the machine-learning recommendations",[26,27,28],"Pneumonia - Bacterial","Urinary Tract Infection Bacterial","Bloodstream Infection",[30,31,32,33,34],"antibiotics","empiric therapy","clinical decision support system","multidrug resistant microorganism","antimicrobial stewardship","NOT_YET_RECRUITING","2026-08-08",{"date":38,"type":39},"2026-08-13","ACTUAL",{"date":41,"type":20},"2026-09",{"date":43,"type":20},"2027-09",{"name":45,"class":46},"Instituto de Investigación Sanitaria Gregorio Marañón","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100624287","phase-3-prediction-and-prevention-of-bloodstream-infections-after-kidney-transplantation-100624287","NCT07407673","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation","Prediction and Prevention of Bloodstream Infections After Kidney Transplantation - The PREDICT Study","PREDICT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Kidney transplant recipient.\n3. Able to provide written informed consent.\n4. ≥1 urine sample with bacteriuria ≥10\\^5 CFU\u002FmL (excluding fungi) within first month post-transplantation.\n\nExclusion Criteria:\n\n1. Known strictures in the esophagus and\u002For obstructions in the gastrointestinal tract including diabetes gastroparesis.\n2. Known hypersensitivity or allergy to β-lactam antibiotics.\n3. Known or suspected genetic metabolism anomalies in the carnitine metabolism, including carnitine transporter defect or organic acidurias such as methylmalonic aciduria or propionic acidaemia.\n4. Individuals of Faroese descent (defined as both biological parents born in the Faroe Islands).\n5. Porphyria.\n6. Current treatment with valproic acid, valproate or other medications liberating pivalic acid.\n7. Current treatment with probenecid.\n8. Current treatment with methotrexate.\n9. Ongoing dialysis one month post-transplantation.\n10. Pregnancy or breastfeeding.",{"count":56,"type":20},180,[58],"PHASE3","Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs). Some of these infections can spread to the bloodstream and cause serious illness, hospitalization, loss of kidney function, or death. Currently, there is no established strategy to prevent these serious bacterial infections in kidney transplant recipients who are at highest risk.\n\nThe PREDICT study is investigating whether a low daily dose of the antibiotic pivmecillinam can reduce the risk of bacterial urinary tract infections and bloodstream infections after kidney transplantation. The study focuses on kidney transplant recipients who have bacteria detected in their urine during the first month after transplantation, as previous research suggests that these patients have a particularly high risk of developing serious infections later.\n\nIn this randomized, double-blind, placebo-controlled trial, 180 adult kidney transplant recipients will be assigned by chance to receive either pivmecillinam or a matching placebo from 1 to 6 months after transplantation. Neither participants nor study staff will know which treatment has been assigned during the study. All participants will continue to receive standard post-transplant care and monitoring.\n\nThe main goal of the study is to determine whether prophylactic pivmecillinam can reduce the occurrence of infections caused by Enterobacterales bacteria, including urinary tract infections and bloodstream infections, during the first 6 months after transplantation. The study will also evaluate the effects of treatment on serious clinical outcomes, safety, quality of life, antimicrobial resistance, and long-term kidney transplant outcomes.\n\nThe study hypothesis is that targeted antibiotic prophylaxis with pivmecillinam in kidney transplant recipients at increased risk of infection will reduce the incidence of Enterobacterales urinary tract infections and bloodstream infections during the high-risk period after transplantation compared with placebo.",[61,28,62,63,64,65,27,66,67],"Kidney Transplant Infection","Kidney Transplant","Kidney Transplant Recipients","Infection","Urinary Tract Infection(UTI)","Antibiotic Prophylaxis","Bacteriuria",[69,70,71,72,73,74,75],"kidney transplantation","bloodstream infection","urinary tract infection","antibiotic prophylaxis","pivmecillinam","bacteriuria","Enterobacterales","2026-07-20",{"date":78,"type":39},"2026-07-22",{"date":80,"type":20},"2027-01-01",{"date":82,"type":20},"2041-07",{"name":84,"class":46},"Susanne Dam Nielsen, MD, DMSc",3,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":17,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100596382","phase-4-betadine-vs-sterile-water-for-periurethral-preparation-100596382","NCT07044726","Betadine vs Sterile Water for Periurethral Preparation","Betadine vs Sterile Water for Periurethral Preparation Prior to Straight Catherization in the Clinic Setting: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 18+\n* Patient undergoing in office straight catherization\n\nExclusion Criteria:\n\n* History of culture proven recurrent urinary tract infection (2 in any 6-month period or 3 in any 12-month period)\n* Urine Analysis with +Nitrites\n* Catherization for any reason in the last 4 weeks\n* History of Iodine allergy\n* Patients unable to speak English\n* Patient does not have the capacity to consent\n* 2-3rd trimester pregnancy",true,"FEMALE",{"count":96,"type":20},148,[98],"PHASE4","The purpose of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water (water that has been treated to remove bacteria and living organisms) vs Betadine also known as Povidone-Iodine (a medical grade cleaning solution) changes the rates of bacteria in the urine after a temporary catheter, or draining tube, is placed into the bladder. Chemical antiseptics, including Betadine, are the current standard of care. An additional goal of this study is to determine whether cleaning of the urethra, or external opening to the bladder, with sterile water vs betadine changes the amount of discomfort or pain patients experience with placement of a temporary catheter, or draining tube, in the bladder.",[101,27],"Catherization",[103,104,101],"Betadine","Sterile Water","RECRUITING","2026-05-01",{"date":108,"type":39},"2026-05-04",{"date":110,"type":39},"2025-06-30",{"date":112,"type":20},"2028-05-21",{"name":114,"class":46},"University of Louisville",2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100628616","relevance-of-the-urine-bacterial-culture-performed-before-transurethral-resection-of-the-bladder-for-post-operative-febrile-urinary-tract-infections-prevention-a-non-inferiority-randomized-controlled-trial-100628616","NCT07463963","Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled Trial","RUPTURE","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Scheduled for TURB surgery for a suspected or confirmed diagnosis of bladder tumor\n* Affiliated person or beneficiary of a social security scheme\n* Written informed consent obtained from the participant\n\nExclusion Criteria:\n\n* Patient with active UTI\n* Planned combined surgery\n* Patient previously included in this research protocol\n* People benefiting from enhanced protection, namely minors, people deprived of their liberty by judicial or administrative decision, people staying in a health or social institution, adults under legal protection\n* Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation : oral, intravaginal, transdermal; Progestogen-only hormonal contraception associated with inhibition of ovulation : oral, injectable, implantable; Intrauterine device; Intrauterine hormone-releasing system; Bilateral tubal occlusion) or permanent sterilization methods ( hysterectomy, bilateral salpingectomy, bilateral oophorectomy).",{"count":124,"type":20},2600,[23],"The main objective of the study is to demonstrate that not performing a systematic UC before the TURB procedure is non-inferior to performing a systematic UC in terms of the incidence of febrile UTIs during the first 30 postoperative days",[128,129,27],"Bladder Cancer","Transurethral Resection of the Bladder",[131],"Urine Culture","2026-04-24",{"date":134,"type":39},"2026-04-30",{"date":136,"type":20},"2026-05-15",{"date":138,"type":20},"2030-08-15",{"name":140,"class":46},"Poitiers University Hospital",15,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":21,"phases":152,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100384904","phase-4-shortened-antibiotic-treatment-of-5-days-in-gram-negative-bacteremia-100384904","NCT04291768","Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia","Short Course Antibiotic Treatment of Gram-negative Bacteremia: A Multicenter, Randomized, Non-blinded, Non-inferiority Interventional Study","GNB5","Inclusion Criteria:\n\n* Age \\>18 years\n* Blood culture positive for Gram-negative bacteria\n* Evidence of urinary tract source of infection (positive urine culture or at least one clinical symptom compatible with urinary tract infection)\n* Antibiotic treatment with antimicrobial activity to Gram-negative bacteria administrated within 12 hours of first blood culture\n* Temperature \\\u003C37.8°C at randomization\n* Clinically stabile at randomization (systolic blood pressure \\> 90 mm Hg, heart rate \\\u003C100 beats\u002Fmin., respiratory rate \\\u003C24\u002Fminute, peripheral oxygen saturation \\> 90 %)\n* Oral and written informed consent\n\nExclusion Criteria:\n\n* Antibiotic treatment (\\>2 day) with antimicrobial activity to Gram-negative bacteria within 14 days of inclusion\n* Gram-negative bacteremia within 30 days of blood culture\n* Immunosuppression (Untreated HIV-infection, Neutropenia (absolute neutrophil count \\\u003C 1.0 x 109\u002Fl), Untreated terminal cancer, Receiving immunosuppressive agents (ATC-code L04A), Corticosteroid treatment (≥20 mg\u002Fday prednisone or the equivalent for \\>14 days) within the last 30 days, Chemotherapy within the last 30 days, Immunosuppressed after solid organ transplantation, Asplenia)\n* Polymicrobial growth in blood culture\n* Bacteremia with non-fermenting Gram-negative bacteria (Acinetobacter spp, Burkholderia spp, Pseudomonas spp), Brucella spp, or Fusobacterium spp\n* Failure to remove source of infection within 72 hours of first blood culture (e.g. change of catheter á demeure)\n* Pregnancy or breastfeeding",{"count":151,"type":20},380,[98],"GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram negative bacteremia with a urinary tract source of infection (GNB).\n\nFive days after initiation of antimicrobial therapy for GNB, participants are randomized 1:1 to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and afebrile. The control group receives antibiotics for a duration of 7 days or longer at the discretion of the treating physician.\n\nThe primary outcome is 90-day survival without clinical or microbiological failure to treatment, which will be tested with a non inferiority margin of 10%.",[155,27],"Gram-negative Bacteremia",[157,158,159,160],"Gram-negative bacteremia","Urinary tract infection","Shortened antibiotic treatment","Bacterial infection","2023-02-06",{"date":163,"type":39},"2023-02-08",{"date":165,"type":39},"2020-03-11",{"date":167,"type":20},"2026-10-01",{"name":169,"class":46},"Thomas Benfield",13]